FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

BD (Becton, Dickinson and Company) , a leading global medical technology company, announced the commercial release of the BD Neopaktm XtraFlowtm Glass Prefillable Syringe and the latest capacity ...

We are excited to see efti in combination with KEYTRUDA now driving a 1.9-fold increase in responses ... E+P continues to ...

Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma ...

Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...

This week, the FDA approved J&J’s JNJ Tremfya for treating an inflammatory bowel disease condition (“IBD”), ulcerative ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

The jab, known as mRNA-4359 and developed by Moderna, is aimed at people with advanced melanoma, lung cancer and other solid ...

A pioneering vaccine designed to train the body to identify and fight cancer cells is showing early signs of success, ...

ChromaDex Corp. , the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, is excited to announce the second wave of intravenous (IV) wellness clinics ...

Injective Labs, the research and development company behind Injective [INJ], has introduced a groundbreaking tokenized index for the BlackRock USD Institutional Digital Liquidity Fund. The BUIDL Index ...